1. Pink Sheet
  2. >>Regulatory Trackers
  3. >>US FDA Performance Tracker

FDA Panel Takes ‘Leap Of Faith’ In Backing Epinephrine Nasal Spray For Anaphylaxis

 
• By Brenda Sandburg

In a split vote, advisory committee finds PK/PD data support favorable benefit-risk assessment of ARS Pharmaceuticals’ neffy, but calls for postmarket studies to evaluate its clinical efficacy.

epinephrine
FDA advisory panel finds PK/PD data supports favorable assessment of intranasal epinephrine for treatment of anaphylaxis • Source: Shutterstock

The US Food and Drug Administration’s Pulmonary-Allergy Drugs Advisory Committee was divided over whether pharmacokinetic and pharmacodynamic data on ARS Pharmaceuticals, Inc.’s intranasal epinephrine is sufficient to support use of the drug for treatment of Type I allergic reactions, including anaphylaxis. While a majority concluded that it was, others said clinical data is needed to show that it is effective.

At its 11 May meeting, the panel voted 16-6 that the PK/PD results support a favorable benefit-risk assessment for the epinephrine nasal spray, ARS-1 or neffy, in adults

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers

AMR-Targeting Drug Secures EMA PRIME Designation

 
• By Neena Brizmohun

Antabio’s next-generation, broad-spectrum antibacterial, MEM-ANT3310, has made it onto the European Medicines Agency’s priority medicines scheme. The company says its product is designed to make a significant impact on the growing problem of antimicrobial resistance.

Global Pharma Guidance Tracker - March 2025

 
• By Vibha Sharma and Anabel Costa-Ferreira

Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

US FDA’s Review Performance Held Steady Despite Stormy First Quarter

 
• By Bridget Silverman

Organizational turmoil has not yet affected reviews of novel agent applications, with Q1 2025 approvals coming in low, but the first quarter share of the entire year is variable.